Live market screen
Commercial Space Company Risk / Opportunity Ranking
Opportunity/risk view across launch, satellites, SAR, earth observation, defense demand, financing events, and execution risk.
Updated June 27, 2026
Opportunity view
Showing rows 81-100 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 81 | Atomic-6 lowweak | Opp 4 Risk 5 | Thesis: Atomic-6 appears to have meaningful strategic upside because the membership rationale says it launched an orbital data center service and has DoD and U.S. Space Force contracts, which would support a long-duration defense/space infrastructure thesis if confirmed. Why now: The reviewed sources rationale cites article and says Atomic-6 launched an orbital data center service and has DoD and U.S. Space Force contracts, but no representative article or is provided in the visible reviewed sources, so timing confidence is limited. Caveats: No direct evidence or article are available in the reviewed sources body. Opportunity thesis relies on membership rationale rather than citable article summary. Because the underlying evidence is not exposed, conviction must stay low. |
| 82 | Beijing Guodian High-Tech Technology Co lowweak | Opp 4 Risk 2 | Thesis: Reviewed evidence rationale says the company received approval for a commercial satellite IoT pilot program using the Tianqi constellation of 41 satellites. Regulatory or pilot approval tied to an existing constellation is a meaningful long-horizon opportunity signal if execution follows. Why now: The implied catalyst is the pilot-program approval, but the reviewed sources provide no retained article summary or timestamped evidence row beyond the membership rationale. Caveats: Phase2 membership rationale references: but the actual summary/evidence are absent. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. Opportunity score is restrained because approval alone is described in rationale but not directly evidenced here. |
| 83 | D-Orbit lowweak | Opp 4 Risk 3 | Thesis: Moderate evidence-ranked opportunity: the reviewed sources membership rationale says D-Orbit partnered with Magdrive for an electric propulsion demo and places the company in satellite propulsion/orbital logistics, which suggests active technology development aligned with durable LEO and sustainability themes over a 1 year+ horizon. Why now: Why now is the partnership/demo claim referenced in article ID, but the reviewed sources includes neither nor explicit article timing beyond the article ID prefix, limiting recency precision. Caveats: Opportunity rests on membership rationale rather than fully available direct evidence. Referenced article ID has no in the reviewed sources. Demo activity is not the same as proven commercial traction. |
| 84 | Dhruva Space lowweak | Opp 4 Risk 2 | Thesis: Among this screen, Dhruva Space has one of the stronger reviewed sources rationales: it is described as having received a government grant for Project Garud, a 500 kg-class satellite platform for constellation-scale missions, and later partnering with ICEYE on satellite systems and Earth observation services. If current, those items imply platform and partnership traction that could matter over a 1 year+ horizon. Why now: The reviewed sources references: and: in the membership rationale, suggesting relatively recent strategic developments, but the coverage report still shows zero evidence after recent evidence window, so timing confidence is limited. Caveats: Positive thesis relies on membership rationale, not available direct evidence. Partnership evidence cannot be expanded through relation propagation beyond what is explicitly stated. |
| 85 | EDGX lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence rationale indicates EDGX is a Belgian spacetech startup with a prior €2.3M seed round and an in-orbit demonstration of its STERNA AI computing system on SpaceX Transporter-16. If still current, in-orbit validation plus prior funding can support a longer-horizon commercialization opportunity. Why now: The membership support references articles, and, implying a narrative of funding plus orbital demonstration, but active evidence remains empty after recent evidence filtering, limiting recency confidence. Caveats: In-orbit demo claim appears only in reviewed sources rationale, not available direct evidence. No evidence confirms whether the prior seed round falls within the current decision horizon relevance. No direct adverse evidence is present, but that is not proof of low fundamental risk. |
| 86 | Ellipsis Drive lowweak | Opp 4 Risk 3 | Thesis: Moderate opportunity on sparse evidence: the reviewed sources membership rationale describes Ellipsis Drive as addressing an Earth observation satellite-data processing bottleneck, with support from space agencies and target users including Earth observation firms. If accurate, that points to a software-layer position that could benefit over a 1 year+ adoption cycle. Why now: Why now is the reviewed sources' claim that the company addresses a key EO data-processing bottleneck and has space-agency support, referenced to article ID: though no or timestamp detail was provided. Caveats: Claims come from membership rationale rather than direct evidence. Referenced article ID: lacks a reviewed sources. Support from agencies and target users is weaker than demonstrated contracted revenue. |
| 87 | Eta Space lowweak | Opp 4 Risk 2 | Thesis: Eta Space has reviewed sources support that its LOXSAT mission will demonstrate 11 cryogenic fluid management technologies in space and that the mission is launched by Rocket Lab for NASA, indicating real technology validation relevance for in-space fueling or orbital servicing over a 1 year+ horizon. Why now: The membership rationale specifically points to the LOXSAT mission demonstration as the current relevance driver, citing article: but the reviewed sources does not include the article or more detailed dated evidence fields. Caveats: Underlying article is not provided in the reviewed sources. Score is based on membership rationale summary rather than available direct evidence. Single-mission validation is weaker than broad commercial traction. |
| 88 | Firefly Aerospace lowweak | Opp 4 Risk 2 | Thesis: Firefly has a positive long-horizon lunar infrastructure angle because recent article context says NASA awarded it a Moon Base contract for MoonFall, a 2028 mission to transport four drones for Artemis-site surveying. Why now: A dated May 26, 2026 article puts a fresh NASA program win into the current evidence window, which can matter over a 1 year+ horizon even if revenue realization is later. Evidence
Caveats: Only one within the recent evidence window article is available. Evidence is supporting article context rather than stronger extracted direct events. Timing of mission realization is long-dated relative to the evidence window. |
| 89 | Hispasat lowweak | Opp 4 Risk 2 | Thesis: The reviewed sources membership rationale states Hispasat is part of the IRIS2 project and will manage the LEO shell. If current, that implies meaningful strategic positioning in a long-duration European satcom infrastructure program. Why now: The only timing clue is the membership rationale referencing article, but the underlying article summary and are not included in these reviewed sources. Recency beyond the batch month label is uncertain. Caveats: No representative article or is available in the reviewed sources despite the favorable rationale. Program-role evidence can be important, but without economics or milestones the opportunity case is incomplete. |
| 90 | Impulse Space lowweak | Opp 4 Risk 4 | Thesis: Membership rationale ties Impulse Space to a Pentagon deal for space-based interceptor prototypes and identifies orbital transfer vehicle relevance, which would be strategically meaningful over a 1 year+ horizon if confirmed with current evidence, but the reviewed sources does not load the underlying evidence or article summaries after recent evidence window, unavailable in reviewed sources). Why now: Why now is only medium because defense-space prototype work can matter over a 1 year+ horizon, but the reviewed sources' available evidence is empty after recent evidence window, preventing higher-conviction ranking. Caveats: No current evidence is provided for. No direct evidence remained after the recent evidence filter. Potential opportunity rests on membership rationale rather than available corroborated evidence. |
| 91 | MDA Space Ltd. lowweak | Opp 4 Risk 3 | Thesis: MDA Space shows some opportunity context from being identified as operating in in-orbit servicing and from an article saying it won a Radarsat replenishment satellite contract, which could support durable government-space demand if current. Why now: Why-now is weak because both available representative articles are undated, so current timing and whether these items remain incremental versus already absorbed is uncertain Evidence
Caveats: Both cited articles are undated; recency is uncertain. Support is weak and based on article context, not direct positive events. No material adverse evidence is available, but no strong current catalyst is validated either. |
| 92 | Modul8 lowweak | Opp 4 Risk 3 | Thesis: Reviewed evidence membership rationale says Modul8 is a spun-out space communications unit with $40m funding, lunar cellular network deployment, and Artemis spacesuit communications work. If still current, that is among the stronger long-horizon strategic opportunity setups in this screen, but the reviewed sources does not provide citeable direct evidence or article. Why now: Among sparse names, the stated combination of funding plus lunar communications program exposure could matter over 1 year+, but recency cannot be validated from served evidence. Caveats: The strongest claims are only in membership rationale and not backed by citeable -bearing evidence in the reviewed sources. No negative evidence does not equal low fundamental risk. |
| 93 | Momentus Inc lowweak | Opp 4 Risk 5 | Thesis: Membership rationale says Momentus secured a new commercial contract for its Vigoride-9 orbital service vehicle and identifies the company as an orbital service vehicle / orbital services platform business, which would support a real opportunity thesis for space logistics if current and corroborated. However, these reviewed sources have no direct evidence or article summaries after recent evidence window, so the opportunity score must stay modest (: and: unavailable in reviewed sources). Why now: Why now is medium because an orbital services contract can matter over a 1 year+ horizon, but the reviewed sources' post-recent evidence window evidentiary absence prevents stronger timing confidence. Caveats: No direct evidence remained after the recent evidence filter. |
| 94 | NEC Corporation lowweak | Opp 4 Risk 2 | Thesis: Membership rationale states NEC launched an Orbital Transfer Vehicle development project selected by JAXA and aims for Asia's first OTV deployment. That would be a credible long-horizon strategic opportunity if current, but the reviewed sources provide no available direct evidence or article summaries inside the recent evidence window to validate progress (: unavailable in reviewed sources). Why now: Why now is medium rather than weak because an OTV development project can be durable over 1 year+, but evidentiary support in the reviewed sources are thin after recent evidence window. Caveats: No current evidence is provided for No direct evidence remained after the recent evidence filter. Current milestone timing is unverified in the reviewed sources. |
| 95 | NewOrbit Space mediummedium | Opp 4 Risk 4 | Thesis: NewOrbit Space has a plausible long-horizon opportunity because an article says it is developing satellites for very low Earth orbit and raised $18.5 million in a Series A round, suggesting both a differentiated technical focus and capital to pursue it. Why now: Why now is weaker than Aavuus because the article has no publication date. The reviewed sources explicitly says no is available and recency-sensitive claims should be treated cautiously., undated Evidence
Caveats: Evidence is supporting article context only, not direct structured positive event evidence. Publication date is unavailable; recency is uncertain. Single-article support only; no independent confirmation. |
| 96 | NorthStar Earth & Space lowweak | Opp 4 Risk 3 | Thesis: NorthStar Earth & Space appears strategically relevant to space domain awareness and may have public-market access or financing optionality via a SPAC path, but these reviewed sources provide only limited supporting article context and no strong in-window direct facts for business traction. Why now: The only dated evidence in this row is an April 27, 2026 article-level summary stating NorthStar Earth & Space plans to go public in a SPAC deal at a $300 million valuation. That may matter over a 1 year+ horizon, but the reviewed sources does not provide stronger company-specific direct evidence here. Evidence
Caveats: Coverage is extremely thin in this row: only one external article and no direct positive or negative dated events. The phase-2 rationale mentions a CAD$40M+ Royal Canadian Air Force contract, but that contract evidence is not directly surfaced in the available evidence fields for this output row, so it should not be elevated beyond the membership rationale. |
| 97 | Obruta Space Solutions lowweak | Opp 4 Risk 4 | Thesis: Obruta operates in a strategically attractive area: autonomous docking for on-orbit servicing and logistics, with stated use cases including inspection, orbital refueling, satellite life extension, debris removal, and orbital logistics. That gives a plausible long-horizon opportunity narrative if product or customer validation emerges. Why now: The only dated visible evidence is a company-site page with a May 20, 2026 describing the technology and target markets, which is relevant for strategic positioning but not enough to prove commercial inflection within the next year. Evidence
Caveats: Evidence is company-site descriptive context only. No third-party validation, financing, contract, or deployment evidence is shown. |
| 98 | Observable Space lowweak | Opp 4 Risk 4 | Thesis: Moderate opportunity based on the reviewed sources membership rationale that Observable Space was listed among notable space startup funding deals at $90 million. A funding round of that size can support growth over a 1 year+ horizon if deployed effectively. Why now: Why now is the funding mention tied to article ID: but the reviewed sources provide no, operating specifics, or additional corroborating evidence. Caveats: Funding alone is positive evidence but does not prove business quality. Article ID: is referenced without. |
| 99 | OMSPACE lowweak | Opp 4 Risk 4 | Thesis: The reviewed sources membership rationale says OMSPACE successfully launched a sounding rocket and plans an orbital launch vehicle by 2027 for small satellites. That suggests a real technical progression path if the company can convert suborbital progress into orbital capability over the next year-plus. Why now: The reviewed sources' rationale references article: for a successful sounding-rocket launch and a 2027 orbital-launch target, but the underlying article summary/ is not included here, limiting recency and sequence assessment. Caveats: Evidence is limited to a broad membership rationale without article detail. A sounding-rocket success is meaningfully earlier-stage than an orbital launch business. Risk and opportunity are both elevated relative to peers because the technology path is ambitious but still lightly evidenced. |
| 100 | Orbital lowweak | Opp 4 Risk 3 | Thesis: Orbital has modest evidence-backed opportunity because a dated within the recent evidence window article says it raised $5 million to fund an in-orbit computing demonstration next year and support initial work on its first purpose-built orbital compute satellite, Orbital-1, slated for 2028, indicating financing plus roadmap progress relevant to a 1 year+ horizon, June 10, 2026). Why now: The recency is relatively fresh: the is based on June 10, 2026, inside the 90-day recent evidence window, and it frames both new capital and a next-year demo as near-to-medium-term strategic milestones. Evidence
Caveats: All retained evidence is weak context supporting article context; there is no direct positive event/fact available. Same-article repeated rows are not independent confirmation. The opportunity case depends on an early-stage roadmap and financing announcement; commercial traction is not directly evidenced in retained rows. |
Risk view
Showing rows 41-60 of 438; 20 rows per page.
| Rank | Company | Score | Thesis / Evidence |
|---|---|---|---|
| 41 | PLD Space highstrong | Opp 8 Risk 4 | Thesis: Execution risk remains meaningful because the key value inflection still depends on MIURA 5 development and inaugural test-flight timing later in 2026 rather than already-proven orbital commercial cadence. Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon. Evidence
Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material. |
| 42 | Rocket Lab USA, Inc. highstrong | Opp 7 Risk 4 | Thesis: Risk is moderate because the reviewed sources' key opportunity is still relatively early in size and scope compared with SpaceX, and execution must extend from launch into GEO satellite production and operation. Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective. Evidence
Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof. |
| 43 | SatSure mediummedium | Opp 7 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources classifies the available evidence mostly as weak supporting article context rather than direct positive events/facts, and there is no available direct evidence for commercial revenue conversion, deployment success, or execution milestones beyond the grant and partnership narratives Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context Evidence
Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones. |
| 44 | Scout Space mediummedium | Opp 6 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources' usable support is mostly supporting article context rather than direct positive events, and the financing is growth capital for a private company rather than proof of commercial conversion at scale. Why now: A dated May 6, 2026 article says Scout raised up to $18 million Series A and will use the capital for mission execution and expansion of manufacturing capabilities, creating a current capacity-building milestone for the next year, May 6, 2026). Evidence
Caveats: Most available support is weak context/supporting article context rather than direct positive events. Blue Origin partnership articles are from 2025 and were outside the 90-day recent evidence window, so they should not drive recency-based ranking |
| 45 | Skyroot Aerospace mediummedium | Opp 5 Risk 4 | Thesis: The main risk is launch execution risk because the reviewed sources frames Vikram-1 as a preparation-stage maiden orbital mission rather than an already completed orbital launch, and there is no additional direct evidence in the reviewed sources showing later de-risking. Why now: The relevant dated development is the reported financing on May 7, 2026 alongside the stated approach to the Vikram-1 maiden flight, which fits a 1 year+ thesis if execution progresses. Evidence
Caveats: Support is supporting article context only; the reviewed sources have no direct positive events available for Skyroot. Same-article repeated context rows are not independent confirmation. |
| 46 | SpaceX highstrong | Opp 9 Risk 4 | Thesis: Risk exists from concentration in large government programs and evidence of pricing tension with the Pentagon, but the reviewed sources does not show a material adverse operational or financial event inside the recent evidence window. Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon. Evidence
Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here. |
| 47 | SpinLaunch lowweak | Opp 4 Risk 4 | Thesis: The same constellation-buildout framing also implies material execution risk because the reviewed sources provide no fresh in-window evidence confirming funding sufficiency, deployment timing, customer demand, or progress beyond the build statement. Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation. |
| 48 | Spire Global, Inc. lowweak | Opp 2 Risk 4 | Thesis: Risk is modestly higher than opportunity because there is effectively no fresh reviewed evidence to validate current traction, contracts, or program wins after the March 29, 2026 cutoff. The issue is not reviewed sources-proven deterioration, but lack of current support. Why now: There is no current catalyst in the kept ranking evidence. The only representative article provided is dated February 7, 2025, outside the recent evidence window, via at Caveats: Zero evidence were kept after the 90-day recent evidence window. The available article context is outside recent evidence window and should not be treated as current catalyst evidence. |
| 49 | Starcloud mediummedium | Opp 6 Risk 4 | Thesis: Starcloud also carries meaningful execution risk because the reviewed sources evidence frames the business around an extremely ambitious proposed constellation scale and supporting article context rather than direct company events. The May 26, 2026 article says the constellation ultimately envisions 88,000 orbital data centers, a very large scope that implies substantial execution and capital intensity risk. Why now: Within the 90-day recent evidence window, Starcloud has the clearest sequence of dated business-state updates: funding on March 30, 2026, network-equipment contract on May 26, 2026, and additional context on capital raised and market positioning on June 10, 2026, For a 1 year+ horizon, that sequence supports an active buildout story even though evidence quality is not fully direct. Evidence
Caveats: All usable evidence is supporting article context; the reviewed sources provide no direct positive or negative dated event/facts. Repeated Starcloud claims across articles are not independent confirmation under the evidence standard. Opportunity and risk both remain dependent on future execution over a long horizon. |
| 50 | Stellar Alpina AG lowweak | Opp 5 Risk 4 | Thesis: The same rationale also implies significant technology and commercialization risk: pre-seed stage, advanced propulsion development, and no available proof of contracts, flight validation, or revenue traction in the reviewed sources. Why now: Why now is relatively better than peers because the rationale includes a recent capital raise and a specific product focus, both of which can influence a 1 year+ strategic trajectory, though no direct dated evidence are available to verify recency sequencing. Caveats: Membership rationale cites article IDs: and: but no are present. The reviewed sources contain no direct positive or negative evidence arrays despite the financing statement in the rationale. Early-stage propulsion development is inherently high-uncertainty, but that is inferred from stage and product type, not from a available adverse article. |
| 51 | TM2SPACE Technologies lowweak | Opp 3 Risk 4 | Thesis: Risk is modest because there is too little available evidence after recent evidence window to support a stronger positive or negative view, making outcome uncertainty high. Why now: The membership rationale references selection for IN-SPACe funding and AI-powered star tracker work using article IDs, and: but no article summaries, or direct evidence are available in these reviewed sources after recent evidence window, so recency and materiality cannot be independently verified from the evidence body. Caveats: No representative articles, or available evidence available to cite directly beyond membership rationale. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Scoring is conservative because reviewed sources support is incomplete in the visible evidence section. |
| 52 | Tomorrow.io lowweak | Opp 5 Risk 4 | Thesis: Risk remains meaningful because the reviewed sources provide only thin support beyond the financing statement; there is no available kept direct positive event detail, customer traction, deployment milestone, or contract evidence to validate execution progress. Why now: The 'why now' is the capital raise described in the reviewed sources' membership rationale via article: but the ranking payload does not include the article or a richer reviewed evidence row, so recency and detail are only partially grounded. Evidence
Caveats: The reviewed sources does not provide the article for the cited membership-support article. This is mainly a financing-backed opportunity thesis, not a contract- or revenue-backed one in these reviewed sources. |
| 53 | Transcelestial lowweak | Opp 5 Risk 4 | Thesis: Risk is moderately elevated because, despite the promising rationale, the reviewed sources show no representative article details, no direct positive evidence, and zero article IDs after recent evidence window in coverage debug. That creates substantial verification and timing uncertainty. Why now: Why now is only moderate because the membership rationale references support references including, and: but the reviewed sources does not provide or article summaries for them. Without visible dated article detail, the near-current business state cannot be confirmed. Caveats: Important claims appear only in the membership rationale; no -bearing direct evidence is exposed. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 54 | True Anomaly highstrong | Opp 8 Risk 4 | Thesis: Risk remains meaningful because the company is tied to a demanding defense-space interceptor effort, and one source notes $50 million of the financing was debt, which adds some balance-sheet/obligation risk. In addition, much of the evidence comes from external articles and company-associated announcements rather than a broader set of independently available direct events. Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis. Evidence
Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously. |
| 55 | Unastella lowweak | Opp 5 Risk 4 | Thesis: Even with the stated Series B and launch success, launch-vehicle companies remain execution- and capital-intensive, and the reviewed sources provide no available evidence on follow-on contracts, cadence, or economics. Risk is therefore still elevated. Why now: Why now is relatively stronger because the rationale includes both funding and a technical milestone, which are durable indicators for a 1 year+ horizon, though exact dates and chronology cannot be checked from the reviewed sources' empty post-recent evidence window evidence tables. Caveats: Membership rationale cites article IDs: and: but no are given. No direct events or summaries are available after recent evidence window, so success claims cannot be quoted from the reviewed sources. Opportunity and risk both reflect a capital-intensive launch model with limited reviewed sources verification. |
| 56 | Univity lowweak | Opp 5 Risk 4 | Thesis: The same evidence implies meaningful execution risk: building a satellite network is capital intensive and ambitious, while the reviewed sources offers only one supporting article and no direct follow-on customer, launch, or technical milestone evidence. Why now: Why now is the claimed funding event and network build plan referenced in article ID: but the reviewed sources does not provide the article or detailed timestamp, so recency is only partially grounded. Caveats: The key claim comes from membership rationale rather than available direct evidence. Article ID: is referenced without a. No evidence of downstream execution, contracts, launches, or adoption is present. |
| 57 | Vantor lowweak | Opp 5 Risk 4 | Thesis: Risk is elevated because the reviewed sources does not expose the underlying article summaries or -bearing evidence for those contract claims inside the ranking section, and coverage debug shows zero article IDs after recent evidence window and zero evidence available after recent evidence window. That leaves execution and verification risk high. Why now: Why now is only moderate because the membership rationale references significant contracts via support references including: but the reviewed sources provide no or representative article detail for citation-quality corroboration. The forecast horizon of 1 year+ could fit contract conversion and constellation expansion if current, but recency cannot be validated from visible article rows. Caveats: The contract and expansion claims appear only in membership rationale text; no representative article with is included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0. |
| 58 | Vast Space mediummedium | Opp 6 Risk 4 | Thesis: Risk remains elevated because the same body of context portrays Vast as pursuing multiple capital-intensive initiatives at once—commercial space stations, NASA contract competition, and now satellite manufacturing. Earlier dated March items about a $500 million raise were outside the recent evidence window and therefore cannot be primary support here, so the retained case still relies on supporting article context rather than direct event/facts, leaving execution and commercialization risk significant, May 19, 2026, May 19, 2026). Why now: The timing case is stronger than peers because the product expansion articles are dated May 19, 2026 and May 20, 2026, within the 90-day recent evidence window, and represent a potentially durable strategic change: moving into satellite buses rather than remaining only a station developer, May 19, 2026, May 20, 2026). Evidence
Caveats: Retained evidence is weak context supporting article context; there are no direct positive event/facts available. The March 2026 financing articles are outside the 90-day recent evidence window and cannot be primary support, even though they appear in representative articles. Several retained rows summarize the same basic product announcement and should not be treated as independent confirmation. |
| 59 | WISeKey International Holding AG lowweak | Opp 3 Risk 4 | Thesis: Execution risk appears elevated because the thesis depends on a planned constellation and post-quantum satellite rollout, yet the reviewed sources lack fresh evidence validating current status. With no direct negative event available, the risk score is driven by uncertainty around plan-to-execution conversion rather than confirmed deterioration. Why now: There is no documented near-term catalyst in the available evidence. Membership support cites article IDs and, but the reviewed sources reports 0 article IDs after recent evidence window and 0 evidence after recent evidence window. Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources does not include or article summaries for citation. Risk is inferred from lack of current execution proof, not from a confirmed adverse event. |
| 60 | Wyvern lowweak | Opp 4 Risk 4 | Thesis: Risk is moderate because the available evidence is undated supporting article context from the company site. Since the basis is explicitly 'undated,' recency-sensitive claims about current constellation readiness, capacity, and commercial position are uncertain. Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing. Evidence
Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown. |